| Index | — | P/E | 10.86 | EPS (ttm) | 0.93 | Insider Own | 3.71% | Shs Outstand | 59.38M | Perf Week | 5.98% |
| Market Cap | 599.78M | Forward P/E | 10.79 | EPS next Y | 0.94 | Insider Trans | -5.05% | Shs Float | 53.87M | Perf Month | 1.10% |
| Enterprise Value | 378.78M | PEG | 0.49 | EPS next Q | 0.14 | Short Float | 11.56% | Perf Quarter | -3.99% | ||
| Income | 58.00M | P/S | 4.41 | EPS this Y | -11.33% | Short Ratio | 5.76 | Perf Half Y | 0.50% | ||
| Sales | 136.00M | P/B | 2.75 | EPS next Y | -15.57% | ROA | 19.25% | Short Interest | 6.23M | Perf YTD | 12.72% |
| Book/sh | 3.67 | P/C | 2.70 | EPS next 5Y | 22.00% | ROE | 32.77% | 52W High | 15.04 -32.85% | Perf Year | -0.39% |
| Cash/sh | 3.74 | P/FCF | 18.18 | EPS past 3/5Y | — | ROIC | 12.90% | 52W Low | 8.01 26.09% | Perf 3Y | 124.44% |
| Dividend Est. | — | EV/EBITDA | 5.26 | Sales past 3/5Y | 119.67% 52.15% | Gross Margin | 94.96% | Volatility | 4.74% 4.59% | Perf 5Y | 2.12% |
| Dividend TTM | — | EV/Sales | 2.79 | EPS Y/Y TTM | — | Oper. Margin | 28.71% | ATR (14) | 0.46 | Perf 10Y | -82.94% |
| Dividend Ex-Date | — | Quick Ratio | 5.12 | Sales Y/Y TTM | 119.35% | Profit Margin | 42.82% | RSI (14) | 43.32 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 5.17 | EPS Q/Q | -88.43% | SMA20 | -2.94% | Beta | 0.97 | Target Price | 25.75 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | 53.85% | SMA50 | -9.35% | Rel Volume | 0.72 | Prev Close | 10.28 |
| Employees | 61 | LT Debt/Eq | 0.00 | Earnings | Nov 03 | SMA200 | -6.06% | Avg Volume | 879.32K | Price | 10.10 |
| IPO Date | Apr 16, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 27.27% 17.06% | Net Debt/EBITDA | -3.07 | Volume | 636,804 | Change | -1.75% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-27-26 | Reiterated | Canaccord Genuity | Buy | $29 → $20 |
| Jul-27-26 | Reiterated | BTIG | Buy | $24 |
| Jul-27-26 | Reiterated | Guggenheim | Buy | $29 → $24 |
| Jun-10-26 | Reiterated | Maxim Group | Buy | $25 → $35 |
| Jun-10-26 | Reiterated | Guggenheim | Buy | $25 → $29 |
| Jun-09-26 | Reiterated | Canaccord Genuity | Buy | $24 → $29 |
| May-08-26 | Reiterated | Guggenheim | Buy | $23 → $25 |
| Mar-10-26 | Reiterated | Guggenheim | Buy | $22 → $23 |
| Dec-30-25 | Reiterated | H.C. Wainwright | Buy | $20 → $26 |
| Nov-06-25 | Reiterated | Cantor Fitzgerald | Overweight | $24 |
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 136 | 106 | 24 | 27 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 8 | 16 | 7 | 3 | — | — | — | — | — | |
| Gross Profit | 130 | 90 | 16 | 25 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 75 | 78 | 55 | 35 | — | — | — | — | — | |
| Research and Development | 14 | 13 | 42 | 40 | — | — | — | — | — | |
| Other Operating Expense | 0 | 3 | 6 | -1 | — | — | — | — | — | |
| Operating Income | 39 | -4 | -87 | -50 | — | — | — | — | — | |
| Interest Expense | 6 | 8 | 7 | 2 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 36 | 99 | 4 | 5 | — | — | — | — | — | |
| Net Income Before Taxes | 70 | 87 | -90 | -46 | — | — | — | — | — | |
| Income Taxes | 12 | 3 | 15 | 0 | — | — | — | — | — | |
| Consolidated Net Income | 58 | 83 | -106 | -46 | — | — | — | — | — | |
| Net Income From Continuing Operations | 58 | 83 | -106 | -46 | — | — | — | — | — | |
| Net Income | 58 | 83 | -106 | -46 | — | — | — | — | — | |
| EPS (Recurring) | 0.96 | 1.40 | -2.28 | -1.30 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.96 | 1.40 | -2.28 | -1.30 | — | — | — | — | — | |
| EPS (Diluted) | 0.93 | 1.35 | -2.28 | -1.30 | — | — | — | — | — | |
| EBITDA | 72 | 99 | -76 | -44 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 10.86 | 6.64 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.38 | 4.65 | 15.99 | 8.49 | — | — | — | — | — | |
| Gross Margin | 95.59 | 84.91 | 66.67 | 92.59 | — | — | — | — | — | |
| Operating Margin | 28.68 | -3.77 | -362.50 | -185.19 | — | — | — | — | — | |
| Net Margin | 42.65 | 78.30 | -441.67 | -170.37 | — | — | — | — | — | |
| Shares Outstanding | 59 | 55 | 46 | 35 | — | — | — | — | — | |
| Market Capitalization | 596 | 493 | 384 | 229 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| McFarlane Neil F. | President and CEO | Oct 12 '26 | Sale | 11.25 | 20,000 | 224,948 | 417,225 | Oct 13 |
| McFarlane Neil F. | President and CEO | Oct 10 '26 | Option Exercise | 0.00 | 50,000 | 0 | 437,225 | Oct 13 |
| Thompson Rahsaan | Chief Legal & Compliance | Aug 14 '26 | Sale | 11.13 | 42,666 | 474,774 | 37,569 | Aug 17 |
| Watton Corey Michael | Director | Aug 10 '26 | Option Exercise | 4.97 | 12,300 | 61,131 | 14,100 | Aug 12 |
| Watton Corey Michael | Director | Aug 10 '26 | Sale | 11.25 | 12,300 | 138,377 | 1,800 | Aug 12 |
| Thompson Rahsaan | Chief Legal & Compliance | Jun 22 '26 | Sale | 12.68 | 34,557 | 438,304 | 80,235 | Jun 23 |
| Thompson Rahsaan | Chief Legal & Compliance | Jun 21 '26 | Option Exercise | 0.00 | 66,667 | 0 | 114,792 | Jun 23 |
| Thompson Rahsaan | Chief Legal & Compliance | May 11 '26 | Sale | 11.30 | 1,794 | 20,272 | 48,125 | May 13 |
| Bode John B | Director | Mar 24 '26 | Option Exercise | 4.93 | 78,400 | 386,512 | 123,400 | Mar 26 |
| McFarlane Neil F. | President and CEO | Feb 09 '26 | Sale | 8.56 | 14,625 | 125,186 | 387,225 | Feb 10 |
| McFarlane Neil F. | President and CEO | Feb 07 '26 | Option Exercise | 0.00 | 37,500 | 0 | 401,850 | Feb 10 |
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller | Feb 03 '26 | Sale | 9.18 | 3,000 | 27,548 | 29,590 | Feb 04 |
| Schafer Joshua | CCO | Feb 03 '26 | Sale | 9.19 | 10,500 | 96,500 | 62,278 | Feb 04 |
| McFarlane Neil F. | President and CEO | Feb 02 '26 | Sale | 9.38 | 91,000 | 853,425 | 364,350 | Feb 02 |
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller | Jan 31 '26 | Option Exercise | 0.00 | 11,666 | 0 | 32,590 | Feb 02 |